Image-guided, urethra-sparing transperineal radiofrequency ablation for benign prostatic hyperplasia: a prospective bicenter outpatient study

Read full text
Authors: Thiago Franchi Nunes, Dênis Szejnfeld, Públio César Cavalcante Viana, Flávio Scavone Stefanini, Vinícius Adami Vayego Fornazari, Tulio Fabiano de Oliveira Leite, Alvaro Sadek Sarkis, Hugo Alexandre Sócrates de Castro
Cited by: 1

Abstract

ablation for benign prostatic hyperplasia: a prospective bicenter outpatient study PURPOSE To evaluate the feasibility, reproducibility, and clinical outcomes of an image-guided, urethra-sparing transperineal radiofrequency ablation (TPTA) strategy for benign prostatic hyperplasia (BPH) in an outpatient interventional radiology setting. METHODSThis was a prospective, bicenter, non-randomized study of consecutive men with moderate-to-severe lower urinary tract symptoms (LUTS) refractory or intolerant to medication treated with ultrasound-guided, urethra-sparing TPTA.Outcomes included the International Prostate Symptom Score (IPSS), quality of life, maximum urinary flow rate (Qmax), post-void residual volume (PVR), prostate volume, prostate-specific antigen (PSA), and ejaculatory function [assessed using the Male Sexual Health Questionnaire-Ejaculatory Dysfunction Short Form (MSHQ-EjD-SF)]; complications were graded using the Clavien-Dindo classification.The primary endpoint was a 12-month change in ejaculatory function; secondary endpoints included composite clinical response (≥ 30% IPSS reduction without retreatment) and urinary and structural changes. RESULTSAt 12 months, clinically meaningful improvements were observed across patient-reported symptoms and concordant objective functional and anatomical parameters in a carefully selected outpatient cohort.The median IPSS decreased from 19.5 at baseline to 5.0 at 6 months and 4.0 at 12 months (P < 0.001), accompanied by sustained increases in the Qmax and reductions in PVR, prostate volume, and PSA (all P < 0.001).Among sexually active men, MSHQ-EjD-SF function scores remained stable during the follow-up period, and antegrade ejaculation was preserved in 90% of patients.The composite clinical response rate (≥ 30% IPSS reduction without retreatment) was 97.1% at both 6 and 12 months, with no device-related Clavien-Dindo ≥ III complications observed. CONCLUSIONThese findings suggest that image-guided, urethra-sparing TPTA is a reproducible outpatient interventional radiology procedure capable of achieving clinically meaningful symptom relief while preserving ejaculatory function, supporting further comparative and multicenter evaluation. CLINICAL SIGNIFICANCEUrethra-sparing TPTA has proven to be a safe, feasible, and effective treatment for LUTS and may represent a minimally invasive and effective alternative for BPH.

Fields of Study & Subjects

Urinary Bladder and Prostate Research Kidney Stones and Urolithiasis Treatments Urological Disorders and Treatments

Publication details

Journal / source
Diagnostic and Interventional Radiology
Publisher
Galenos Yayinevi
Publication date
2 March 2026
Language
EN